Switch theme
Sign up to access all valuation multiples
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
2022
256
LTM Revenue $5.1M
LTM EBITDA -$792M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biohaven has a last 12-month revenue (LTM) of $5.1M and a last 12-month EBITDA of -$792M.
In the most recent fiscal year, Biohaven achieved revenue of n/a and an EBITDA of -$877M.
Biohaven expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biohaven valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $4.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$792M | XXX | -$877M | XXX | XXX | XXX |
| EBITDA Margin | -15646% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$837M | XXX | -$885M | XXX | XXX | XXX |
| EBIT Margin | -16535% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$819M | XXX | -$846M | XXX | XXX | XXX |
| Net Margin | -16166% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biohaven's stock price is $15.
Biohaven has current market cap of $1.5B, and EV of $1.2B.
See Biohaven trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.5B | XXX | XXX | XXX | XXX | $-8.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biohaven has market cap of $1.5B and EV of $1.2B.
Biohaven's trades at n/a EV/Revenue multiple, and -1.4x EV/EBITDA.
Equity research analysts estimate Biohaven's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biohaven has a P/E ratio of -1.8x.
See valuation multiples for Biohaven and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 241.9x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBIT | -1.5x | XXX | -1.4x | XXX | XXX | XXX |
| EV/Gross Profit | 287.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.8x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | -3.6x | XXX | -2.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiohaven's last 12 month revenue growth is 985%
Biohaven's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.5M for the same period.
Biohaven's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biohaven's rule of X is -13184% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biohaven and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 985% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -15646% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -13184% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biohaven acquired XXX companies to date.
Last acquisition by Biohaven was XXXXXXXX, XXXXX XXXXX XXXXXX . Biohaven acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biohaven founded? | Biohaven was founded in 2022. |
| Where is Biohaven headquartered? | Biohaven is headquartered in United States of America. |
| How many employees does Biohaven have? | As of today, Biohaven has 256 employees. |
| Who is the CEO of Biohaven? | Biohaven's CEO is Dr. Vlad Coric, M.D.. |
| Is Biohaven publicy listed? | Yes, Biohaven is a public company listed on NYS. |
| What is the stock symbol of Biohaven? | Biohaven trades under BHVN ticker. |
| When did Biohaven go public? | Biohaven went public in 2022. |
| Who are competitors of Biohaven? | Similar companies to Biohaven include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biohaven? | Biohaven's current market cap is $1.5B |
| What is the current revenue of Biohaven? | Biohaven's last 12 months revenue is $5.1M. |
| What is the current revenue growth of Biohaven? | Biohaven revenue growth (NTM/LTM) is 985%. |
| What is the current EV/Revenue multiple of Biohaven? | Current revenue multiple of Biohaven is 241.9x. |
| Is Biohaven profitable? | Yes, Biohaven is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biohaven? | Biohaven's last 12 months EBITDA is -$792M. |
| What is Biohaven's EBITDA margin? | Biohaven's last 12 months EBITDA margin is -15646%. |
| What is the current EV/EBITDA multiple of Biohaven? | Current EBITDA multiple of Biohaven is -1.5x. |
| What is the current FCF of Biohaven? | Biohaven's last 12 months FCF is -$340M. |
| What is Biohaven's FCF margin? | Biohaven's last 12 months FCF margin is -6722%. |
| What is the current EV/FCF multiple of Biohaven? | Current FCF multiple of Biohaven is -3.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
